This Is IVL Amplified.TM
Calcified arterial disease is a significant challenge affecting patients around the world — one with limited treatment options. But a groundbreaking way to combat this dangerous disease is here: Pulse IVL™.
Discover Pulse IVL™
A New Way to Combat Severe Calcified Arterial Disease
With its unique Mechanism of Action (MOA), Pulse IVL™ uses high-frequency pulsatile pressure waves to fracture arterial calcium. And through its improved deliverability and intuitive design, our innovative intravascular lithotripsy system is here to give healthcare providers an effective, efficient tool to help patients restore blood flow.
A New Era of IVL
Discover how Pulse IVL™ enables improved deliverability and empowers physicians to treat patients more effectively and efficiently.
A Fundamentally Different MOA
Our system uses a unique MOA — converting pressurized CO2 into pulsatile energy waves at a rate of 15/second that uniformly and multi-directionally radiate along the entire length of the balloon to fracture calcium while expanding the vessel.
Learn MoreProficient from Pre-Clinical to Pivotal IDE
Developed to increase blood flow and improve patients’ ability to walk, Pulse IVL™ is establishing a new treatment option for calcified arterial disease.
Peripheral Clinical Evidence
In several pre-clinical models, Pulse IVL™ was shown to be effective in simultaneously achieving luminal expansion while producing full-thickness calcium fractures in diseased arteries in both concentric and eccentric lesions.
Learn More
Coronary Clinical Evidence
Due to the excellent results in treating calcified lesions in peripheral clinical models, we are working to achieve these same beneficial outcomes for patients with coronary artery disease.
Carotid Clinical Evidence
We believe the treatment efficiency benefits of Pulse IVL™ will be especially meaningful in treating carotid artery disease. Plans are underway to expand our system’s capabilities into carotid clinical models.
Trusted by Experts at the World’s Leading Hospitals
Nicolas W. Shammas, MD, FACS, FSCAI, FSVM, President and Director of the Midwest Cardiovascular Research Foundation 
Chris Metzger, MD, Interventional Cardiologist, National Principal Investigator of the POWER PAD II US IDE Study 
Jon George, MD, Interventional Cardiologist and Endovascular Medicine Specialist, Investigator in the POWER PAD I FIH Study 